OKUR
OnKure Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$59.89M
P/E Ratio
—
EPS
$-4.40
Beta
—
52W High
$4.75
52W Low
$1.70
50-Day MA
$3.18
200-Day MA
$2.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About OnKure Therapeutics, Inc.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company is headquartered in Boulder, Colorado.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-62.50M |
| Operating Margin | 0.00% |
| Return on Equity | -74.40% |
| Return on Assets | -44.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.11 |
| Price-to-Book | 1.05 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.67M |
| Float | $5.26M |
| % Insiders | 1.71% |
| % Institutions | 83.78% |
Analyst Ratings
Consensus ($20.20 target)
6
BuyData last updated: 4/9/2026